— Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter of 2019, vs $0.03 per share loss expected.
— Initiated ENHANCE-IT study of MAT9001 against Vascepa. Topline data expected Q4 2020.
— Cash, cash equivalents and marketable securities at December 31, 2019 were approx. $27.8 million, compared to $12.4 million a year ago.
— MTNB shares ended down 2.75% in its last trading session on Friday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
T Earnings: All you need to know about AT&T’s Q1 2024 earnings results
AT&T Inc. (NYSE: T) reported its first quarter 2024 earnings results today. Revenues dipped slightly to $30 billion from $30.1 billion in the year-ago quarter. Net income attributable to common
V Earnings: All you need to know about Visa’s Q2 2024 earnings results
Visa (NYSE: V) reported its second quarter 2024 earnings results today. Net revenue increased 10% year-over-year to $8.8 billion. GAAP net income grew 10% to $4.7 billion and EPS rose
Tesla (TSLA) reports lower Q1 revenue and earnings; results miss estimates
Electric vehicle giant Tesla Inc. (NASDAQ: TSLA) Tuesday reported lower revenues and earnings, on an adjusted basis, for the first quarter of 2024. The Austin-based carmaker said its first-quarter revenues
